Efficacy News and Research

RSS
Real-world vaccine effectiveness of mRNA-1273 and BNT1262b2 in immunocompromised adults

Real-world vaccine effectiveness of mRNA-1273 and BNT1262b2 in immunocompromised adults

Pfizer COVID-19 vaccine-associated tinnitus responds to transcranial magnetic stimulation

Pfizer COVID-19 vaccine-associated tinnitus responds to transcranial magnetic stimulation

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Unmarried heart failure patients lack confidence to manage their condition, study says

Unmarried heart failure patients lack confidence to manage their condition, study says

Study reveals how ZBP1 could lead to a cytokine storm during COVID-19

Study reveals how ZBP1 could lead to a cytokine storm during COVID-19

Important methodology for targeting conserved epitopes of SARS-CoV-2 and an immune-focused approach in pan-sarbeco and universal CoV vaccine design

Important methodology for targeting conserved epitopes of SARS-CoV-2 and an immune-focused approach in pan-sarbeco and universal CoV vaccine design

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

Multi-center trial shows promising results for implant-free interatrial shunt device to treat heart failure patients

Multi-center trial shows promising results for implant-free interatrial shunt device to treat heart failure patients

Evaluating serum levels of S100A9 as an inflammatory marker of unfavorable outcomes in patients with COVID-19

Evaluating serum levels of S100A9 as an inflammatory marker of unfavorable outcomes in patients with COVID-19

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

Ensitrelvir demonstrates swift SARS-CoV-2 clearance and safety among individuals with asymptomatic, mild, or moderate SARS-CoV-2 infections

Ensitrelvir demonstrates swift SARS-CoV-2 clearance and safety among individuals with asymptomatic, mild, or moderate SARS-CoV-2 infections

Natural immunity weak and short-lived in unvaccinated after Omicron infection

Natural immunity weak and short-lived in unvaccinated after Omicron infection

Parental hesitancy and childhood COVID vaccination

Parental hesitancy and childhood COVID vaccination

Study validates long-term safety and efficacy of Harmony transcatheter pulmonary valve implant

Study validates long-term safety and efficacy of Harmony transcatheter pulmonary valve implant

Molecular profiling of diseased joints could transform treatment for rheumatoid arthritis patients

Molecular profiling of diseased joints could transform treatment for rheumatoid arthritis patients

Scientists investigate relevance of COVID-19 vaccine-mediated T cell immunity to SARS-CoV-2 variants

Scientists investigate relevance of COVID-19 vaccine-mediated T cell immunity to SARS-CoV-2 variants

Impact of COVID-19 second booster vaccine on all-cause death among older cohorts

Impact of COVID-19 second booster vaccine on all-cause death among older cohorts

Neutralizing antibody responses induced by COVID-19 vaccines against SARS-CoV-2 variants

Neutralizing antibody responses induced by COVID-19 vaccines against SARS-CoV-2 variants

Using 'off-the-shelf' engineered stem cell based therapy for treating glioblastomas post-surgery

Using 'off-the-shelf' engineered stem cell based therapy for treating glioblastomas post-surgery

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.